Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients : a position paper from the International Lipid Expert Panel (ILEP)
© 2022 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders..
Statin intolerance is a clinical syndrome whereby adverse effects (AEs) associated with statin therapy [most commonly statin-associated muscle symptoms (SAMS)] result in the discontinuation of therapy and consequently increase the risk of adverse cardiovascular outcomes. However, complete statin intolerance occurs in only a small minority of treated patients (estimated prevalence of only 3-5%). Many perceived AEs are misattributed (e.g. physical musculoskeletal injury and inflammatory myopathies), and subjective symptoms occur as a result of the fact that patients expect them to do so when taking medicines (the nocebo/drucebo effect)-what might be truth even for over 50% of all patients with muscle weakness/pain. Clear guidance is necessary to enable the optimal management of plasma in real-world clinical practice in patients who experience subjective AEs. In this Position Paper of the International Lipid Expert Panel (ILEP), we present a step-by-step patient-centred approach to the identification and management of SAMS with a particular focus on strategies to prevent and manage the nocebo/drucebo effect and to improve long-term compliance with lipid-lowering therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Journal of cachexia, sarcopenia and muscle - 13(2022), 3 vom: 16. Juni, Seite 1596-1622 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Penson, Peter E [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Drucebo effect |
|---|
| Anmerkungen: |
Date Completed 17.08.2022 Date Revised 21.09.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/jcsm.12960 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM344878422 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM344878422 | ||
| 003 | DE-627 | ||
| 005 | 20231226023800.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/jcsm.12960 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1149.xml |
| 035 | |a (DE-627)NLM344878422 | ||
| 035 | |a (NLM)35969116 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Penson, Peter E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients |b a position paper from the International Lipid Expert Panel (ILEP) |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.08.2022 | ||
| 500 | |a Date Revised 21.09.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders. | ||
| 520 | |a Statin intolerance is a clinical syndrome whereby adverse effects (AEs) associated with statin therapy [most commonly statin-associated muscle symptoms (SAMS)] result in the discontinuation of therapy and consequently increase the risk of adverse cardiovascular outcomes. However, complete statin intolerance occurs in only a small minority of treated patients (estimated prevalence of only 3-5%). Many perceived AEs are misattributed (e.g. physical musculoskeletal injury and inflammatory myopathies), and subjective symptoms occur as a result of the fact that patients expect them to do so when taking medicines (the nocebo/drucebo effect)-what might be truth even for over 50% of all patients with muscle weakness/pain. Clear guidance is necessary to enable the optimal management of plasma in real-world clinical practice in patients who experience subjective AEs. In this Position Paper of the International Lipid Expert Panel (ILEP), we present a step-by-step patient-centred approach to the identification and management of SAMS with a particular focus on strategies to prevent and manage the nocebo/drucebo effect and to improve long-term compliance with lipid-lowering therapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Drucebo effect | |
| 650 | 4 | |a Nocebo effect | |
| 650 | 4 | |a SAMS | |
| 650 | 4 | |a Statin intolerance | |
| 650 | 7 | |a Hydroxymethylglutaryl-CoA Reductase Inhibitors |2 NLM | |
| 650 | 7 | |a Lipids |2 NLM | |
| 700 | 1 | |a Bruckert, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Marais, David |e verfasserin |4 aut | |
| 700 | 1 | |a Reiner, Željko |e verfasserin |4 aut | |
| 700 | 1 | |a Pirro, Matteo |e verfasserin |4 aut | |
| 700 | 1 | |a Sahebkar, Amirhossein |e verfasserin |4 aut | |
| 700 | 1 | |a Bajraktari, Gani |e verfasserin |4 aut | |
| 700 | 1 | |a Mirrakhimov, Erkin |e verfasserin |4 aut | |
| 700 | 1 | |a Rizzo, Manfredi |e verfasserin |4 aut | |
| 700 | 1 | |a Mikhailidis, Dimitri P |e verfasserin |4 aut | |
| 700 | 1 | |a Sachinidis, Alexandros |e verfasserin |4 aut | |
| 700 | 1 | |a Gaita, Dan |e verfasserin |4 aut | |
| 700 | 1 | |a Latkovskis, Gustavs |e verfasserin |4 aut | |
| 700 | 1 | |a Mazidi, Mohsen |e verfasserin |4 aut | |
| 700 | 1 | |a Toth, Peter P |e verfasserin |4 aut | |
| 700 | 1 | |a Pella, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Alnouri, Fahad |e verfasserin |4 aut | |
| 700 | 1 | |a Postadzhiyan, Arman |e verfasserin |4 aut | |
| 700 | 1 | |a Yeh, Hung-I |e verfasserin |4 aut | |
| 700 | 1 | |a Mancini, G B John |e verfasserin |4 aut | |
| 700 | 1 | |a von Haehling, Stephan |e verfasserin |4 aut | |
| 700 | 1 | |a Banach, Maciej |e verfasserin |4 aut | |
| 700 | 0 | |a International Lipid Expert Panel (ILEP) |e verfasserin |4 aut | |
| 700 | 1 | |a Acosta, Julio |e investigator |4 oth | |
| 700 | 1 | |a Al-Khnifsawi, Mutaz |e investigator |4 oth | |
| 700 | 1 | |a Alnouri, Fahad |e investigator |4 oth | |
| 700 | 1 | |a Amar, Fahma |e investigator |4 oth | |
| 700 | 1 | |a Atanasov, Atanas G |e investigator |4 oth | |
| 700 | 1 | |a Bajraktari, Gani |e investigator |4 oth | |
| 700 | 1 | |a Banach, Maciej |e investigator |4 oth | |
| 700 | 1 | |a Bhaskar, Sonu |e investigator |4 oth | |
| 700 | 1 | |a Bytyçi, Ibadete |e investigator |4 oth | |
| 700 | 1 | |a Bjelakovic, Bojko |e investigator |4 oth | |
| 700 | 1 | |a Bruckert, Eric |e investigator |4 oth | |
| 700 | 1 | |a Cafferata, Alberto |e investigator |4 oth | |
| 700 | 1 | |a Ceska, Richard |e investigator |4 oth | |
| 700 | 1 | |a Cicero, Arrigo F G |e investigator |4 oth | |
| 700 | 1 | |a Collet, Xavier |e investigator |4 oth | |
| 700 | 1 | |a Daccord, Magdalena |e investigator |4 oth | |
| 700 | 1 | |a Descamps, Olivier |e investigator |4 oth | |
| 700 | 1 | |a Djuric, Dragan |e investigator |4 oth | |
| 700 | 1 | |a Durst, Ronen |e investigator |4 oth | |
| 700 | 1 | |a Ezhov, Marat V |e investigator |4 oth | |
| 700 | 1 | |a Fras, Zlatko |e investigator |4 oth | |
| 700 | 1 | |a Gaita, Dan |e investigator |4 oth | |
| 700 | 1 | |a Hernandez, Adrian V |e investigator |4 oth | |
| 700 | 1 | |a Jones, Steven R |e investigator |4 oth | |
| 700 | 1 | |a Jozwiak, Jacek |e investigator |4 oth | |
| 700 | 1 | |a Kakauridze, Nona |e investigator |4 oth | |
| 700 | 1 | |a Kallel, Amani |e investigator |4 oth | |
| 700 | 1 | |a Katsiki, Niki |e investigator |4 oth | |
| 700 | 1 | |a Khera, Amit |e investigator |4 oth | |
| 700 | 1 | |a Kostner, Karam |e investigator |4 oth | |
| 700 | 1 | |a Kubilius, Raimondas |e investigator |4 oth | |
| 700 | 1 | |a Latkovskis, Gustavs |e investigator |4 oth | |
| 700 | 1 | |a Mancini, G B John |e investigator |4 oth | |
| 700 | 1 | |a Marais, A David |e investigator |4 oth | |
| 700 | 1 | |a Martin, Seth S |e investigator |4 oth | |
| 700 | 1 | |a Martinez, Julio Acosta |e investigator |4 oth | |
| 700 | 1 | |a Mazidi, Mohsen |e investigator |4 oth | |
| 700 | 1 | |a Mikhailidis, Dimitri P |e investigator |4 oth | |
| 700 | 1 | |a Mirrakhimov, Erkin |e investigator |4 oth | |
| 700 | 1 | |a Miserez, Andre R |e investigator |4 oth | |
| 700 | 1 | |a Mitchenko, Olena |e investigator |4 oth | |
| 700 | 1 | |a Mitkovskaya, Natalya P |e investigator |4 oth | |
| 700 | 1 | |a Moriarty, Patrick M |e investigator |4 oth | |
| 700 | 1 | |a Nabavi, Seyed Mohammad |e investigator |4 oth | |
| 700 | 1 | |a Nair, Devaki |e investigator |4 oth | |
| 700 | 1 | |a Panagiotakos, Demosthenes B |e investigator |4 oth | |
| 700 | 1 | |a Paragh, György |e investigator |4 oth | |
| 700 | 1 | |a Pella, Daniel |e investigator |4 oth | |
| 700 | 1 | |a Penson, Peter E |e investigator |4 oth | |
| 700 | 1 | |a Petrulioniene, Zaneta |e investigator |4 oth | |
| 700 | 1 | |a Pirro, Matteo |e investigator |4 oth | |
| 700 | 1 | |a Postadzhiyan, Arman |e investigator |4 oth | |
| 700 | 1 | |a Puri, Raman |e investigator |4 oth | |
| 700 | 1 | |a Reda, Ashraf |e investigator |4 oth | |
| 700 | 1 | |a Reiner, Željko |e investigator |4 oth | |
| 700 | 1 | |a Radenkovic, Dina |e investigator |4 oth | |
| 700 | 1 | |a Rakowski, Michał |e investigator |4 oth | |
| 700 | 1 | |a Riadh, Jemaa |e investigator |4 oth | |
| 700 | 1 | |a Richter, Dimitri |e investigator |4 oth | |
| 700 | 1 | |a Rizzo, Manfredi |e investigator |4 oth | |
| 700 | 1 | |a Ruscica, Massimiliano |e investigator |4 oth | |
| 700 | 1 | |a Sahebkar, Amirhossein |e investigator |4 oth | |
| 700 | 1 | |a Sattar, Naveed |e investigator |4 oth | |
| 700 | 1 | |a Serban, Maria-Corina |e investigator |4 oth | |
| 700 | 1 | |a Shehab, Abdullah M A |e investigator |4 oth | |
| 700 | 1 | |a Shek, Aleksandr B |e investigator |4 oth | |
| 700 | 1 | |a Sirtori, Cesare R |e investigator |4 oth | |
| 700 | 1 | |a Stefanutti, Claudia |e investigator |4 oth | |
| 700 | 1 | |a Tomasik, Tomasz |e investigator |4 oth | |
| 700 | 1 | |a Toth, Peter P |e investigator |4 oth | |
| 700 | 1 | |a Viigimaa, Margus |e investigator |4 oth | |
| 700 | 1 | |a Valdivielso, Pedro |e investigator |4 oth | |
| 700 | 1 | |a Vinereanu, Dragos |e investigator |4 oth | |
| 700 | 1 | |a Vohnout, Branislav |e investigator |4 oth | |
| 700 | 1 | |a von Haehling, Stephan |e investigator |4 oth | |
| 700 | 1 | |a Vrablik, Michal |e investigator |4 oth | |
| 700 | 1 | |a Wong, Nathan D |e investigator |4 oth | |
| 700 | 1 | |a Yeh, Hung-I |e investigator |4 oth | |
| 700 | 1 | |a Zhisheng, Jiang |e investigator |4 oth | |
| 700 | 1 | |a Zirlik, Andreas |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of cachexia, sarcopenia and muscle |d 2010 |g 13(2022), 3 vom: 16. Juni, Seite 1596-1622 |w (DE-627)NLM207308543 |x 2190-5991 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2022 |g number:3 |g day:16 |g month:06 |g pages:1596-1622 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/jcsm.12960 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2022 |e 3 |b 16 |c 06 |h 1596-1622 | ||